Chinese Journal of Pharmacovigilance ›› 2024, Vol. 21 ›› Issue (2): 229-234.
DOI: 10.19803/j.1672-8629.20230152
Previous Articles Next Articles
WANG Xin, SHI Leilei, ZHANG Yuhan, XIE Yundong*, LIU Jiping
Received:
2023-03-21
Online:
2024-02-15
Published:
2024-02-06
CLC Number:
WANG Xin, SHI Leilei, ZHANG Yuhan, XIE Yundong, LIU Jiping. The role of MRPs transporters in drug-induced liver injury[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 229-234.
[1] YAO KY, ZHANG SQ, JIN R, et al.Comparative study on date set of drug-induced liver injury[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2023, 20(5): 568-573. [2] SHEN T, LIU Y, SHANG J, et al.Incidence and etiology of drug-induced liver injury in mainland China[J]. Gastroenterology, 2019, 156(8): 2230-2241. [3] LIU RJ, XIN XJ.Research advances in pathogenesis, risk factors, monitoring, and retreatment of drug-induced liver injury[J]. Journal of Clinical Hepatology(临床肝胆病杂志), 2023, 39(4): 968-973. [4] WANG ST, QIU CX, WANG FL, et al.Research progress in safety of herb-drug interactions mediated by metabolizing enzymes and transporters[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(1): 18-23. [5] BICKERS SC, BENLEKBIR S, RUBINSTEIN JL, et al. Structure of Ycf1p reveals the transmembrane domain TMD0 and the regulatory region of ABCC transporters[J]. Proc Natl Acad Sci USA, 2021, 118(21): eiti2121118. [6] WANG JQ, YANG Y, CAI CY, et al.Multidrug resistance proteins (MRPs): structure, function and the overcoming of cancer multidrug resistance[J]. Drug Resist Updat, 2021, 54: 100743. [7] ZHANG YK, WANG YJ, GUPTA P, et al.Multidrug resistance proteins (MRPs) and cancer therapy[J]. AAPS J, 2015, 17(4): 802-812. [8] CONSEIL G, COLE S.The first cytoplasmic loop in the core structure of the ABCC1 (multidrug resistance protein 1; MRP1) transporter contains multiple amino acids essential for its expression[J]. Int J Mol Sci, 2021, 22(18): 9718. [9] YIN JY, ZHANG J.Multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphism: from discovery to clinical application[J]. Journal of Central South University(Medical Scienses)(中南大学学报医学版), 2011, 36(10): 927-938. [10] COLE SP.Targeting multidrug resistance protein 1 (MRP1, ABCC1): past, present, and future[J]. Annu Rev Pharmacol Toxicol, 2014, 54: 95-117. [11] ZHANG Y, ZHANG Y, LI J, et al.The role of hepatic antioxidant capacity and hepatobiliary transporter in liver injury induced by isopsoralen in zebrafish larvae[J]. Hum Exp Toxicol, 2019, 38(1): 36-44. [12] DU FB, MEI XD.The progress of multidrug resistance-associated protein 2(MRP2) and its role in cancer drug resistance[J]. Journal of Modern Oncology(现代肿瘤医学), 2008(3): 478-480. [13] CHEN Z, SHI T, ZHANG L, et al.Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: a review of the past decade[J]. Cancer Lett, 2016, 370(1): 153-164. [14] WU L, LI Y, SONG Y, et al.A recurrent ABCC2 p.G693R mutation resulting in loss of function of MRP2 and hyperbilirubinemia in Dubin-Johnson syndrome in China[J]. Orphanet J Rare Dis, 2020, 15(1): 74. [15] OU QQ, QIAN XH, LI DY, et al.Yinzhihuang attenuates ANIT-induced intrahepatic cholestasis in rats through upregulation of Mrp2 and Bsep expressions[J]. Pediatr Res, 2016, 79(4): 589-595. [16] ZONG SD, ZHANG H.Research progress of MRP3 and MRP4 transporters in tumor[J]. Chinese Journal of Clinical Pharmacology and Therapeutics(中国临床药理学与治疗学), 2019, 24(3): 327-331. [17] ALI I, WELCH MA, LU Y, et al.Identification of novel MRP3 inhibitors based on computational models and validation using an in vitro membrane vesicle assay[J]. Eur J Pharm Sci, 2017, 103: 52-59. [18] JEONG ES, KIM G, SHIN HJ, et al.Increased serum bile acid concentration following low-dose chronic administration of thioacetamide in rats, as evidenced by metabolomic analysis[J]. Toxicol Appl Pharmacol, 2015, 288(2): 213-222. [19] BANERJEE M, MARENSI V, CONSEIL G, et al.Polymorphic variants of MRP4/ABCC4 differentially modulate the transport of methylated arsenic metabolites and physiological organic anions[J]. Biochem Pharmacol, 2016, 120: 72-82. [20] KOCK K, FERSLEW BC, NETTERBERG I, et al.Risk factors for development of cholestatic drug-induced liver injury: inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4[J]. Drug Metab Dispos, 2014, 42(4): 665-674. [21] OSTUNI A, CASTIGLIONE MM, CUVIELLO F, et al.Structural characterization of the L0 cytoplasmic loop of human multidrug resistance protein 6 (MRP6)[J]. Biochim Biophys Acta Biomembr, 2019, 1861(2): 380-386. [22] WU Y, WU SM.Protective effects of extracts of Sibraea angustata on hepatic injury induced by combining isoniazid with rifampicin in mice[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2010, 30(19): 1660-1663. [23] WANG HG, WU Y, YUE HP.The effect of extracts Sibraea angustata on the expression of Mrp2 and Mrp6 of INH- induced hepatotoxicity in mice[J]. Lishizhen Medicine and Materia Medica Research(时珍国医国药), 2016, 27(11): 2594-2595. [24] HONORAT M, TERREUX R, FALSON P, et al.Localization of putative binding sites for cyclic guanosine monophosphate and the anti-cancer drug 5-fluoro-2’-deoxyuridine-5’-monophosphate on ABCC11 in silico models[J]. BMC Struct Biol, 2013, 13: 7. [25] SODANI K, PATEL A, KATHAWALA RJ, et al.Multidrug resistance associated proteins in multidrug resistance[J]. Chin J Cancer, 2012, 31(2): 58-72. [26] ISHIKAWA T, TOYODA Y, YOSHIURA K, et al.Pharmacogenetics of human ABC transporter ABCC11: new insights into apocrine gland growth and metabolite secretion[J]. Front Genet, 2012, 3: 306. [27] YUN H, WU X, DING Y, et al.Exploring the mechanism of swertia mussotii Franch. for hepatoprotective effects with iTRAQ LC-MS/MS[J]. Comb Chem High Throughput Screen, 2021, 24(9): 1332-1339. [28] PHAM DH, KUDIRA R, XU L, et al.Deleterious variants in abcc12 are detected in idiopathic chronic cholestasis and cause intrahepatic bile duct loss in model organisms[J]. Gastroenterology, 2021, 161(1): 287-300. [29] MEGARAJ V, IIDA T, JUNGSUWADEE P, et al.Hepatobiliary disposition of 3alpha,6alpha,7alpha,12alpha-tetrahydroxy-cholanoyl taurine: a substrate for multiple canalicular transporters[J]. Drug Metab Dispos, 2010, 38(10): 1723-1730. [30] CSANDL MA, CONSEIL G, COLE SP.Cysteinyl leukotriene receptor 1/2 antagonists nonselectively modulate organic anion transport by multidrug resistance proteins (MRP1-4)[J]. Drug Metab Dispos, 2016, 44(6): 857-866. [31] XU R, WANG Q, ZHANG J, et al.Changes in pharmacokinetic profiles of acetaminophen and its glucuronide after pretreatment with combinations of N-acetylcysteine and either glycyrrhizin, silibinin or spironolactone in rat[J]. Xenobiotica, 2014, 44(6): 541-546. [32] JIA Y, LIU Z, HUO X, et al.Enhancement effect of resveratrol on the intestinal absorption of bestatin by regulating PEPT1, MDR1 and MRP2 [33] GREEN BR, BAIN LJ.Mrp2 is involved in the efflux and disposition of fosinopril[J]. J Appl Toxicol, 2013, 33(6): 458-465. [34] ZALUPS RK, JOSHEE L, BRIDGES CC.Novel Hg2+-induced nephropathy in rats and mice lacking Mrp2: evidence of axial heterogeneity in the handling of Hg2+ along the proximal tubule[J]. Toxicol Sci, 2014, 142(1): 250-260. [35] MCGILL MR, JAESCHKE H.Animal models of drug-induced liver injury[J]. Biochim Biophys Acta Mol Basis Dis, 2019, 1865(5): 1031-1039. [36] JING J, HE TT, BAI ZF, et al.An excerpt from AASLD Practice Guidance on drug, herbal and dietary supplement-induced liver injury[J]. Journal of Clinical Hepatology(临床肝胆病杂志), 2022, 38(10): 2219-2223. [37] HOSACK T, DAMRY D, BISWAS S.Drug-induced liver injury: a comprehensive review[J]. Therap Adv Gastroenterol, 2023, 16: 1108346386. [38] KOENDERINK JB, VAN DEN HEUVEL J, BILOS A, et al. Human multidrug resistance protein 4 (MRP4) is a cellular efflux transporter for paracetamol glutathione and cysteine conjugates[J]. Arch Toxicol, 2020, 94(9): 3027-3032. [39] QU X, ZHANG Y, ZHANG S, et al.Dysregulation of BSEP and MRP2 may play an important role in isoniazid-induced liver injury via the SIRT1/FXR pathway in rats and HepG2 Cells[J]. Biol Pharm Bull, 2018, 41(8): 1211-1218. [40] FENG H.Research progress on drug-induced cholestasis induced liver injury[J]. Modern Medicine and Health Research Electronic Journal(现代医学与健康研究电子杂志), 2021, 5(8): 132-135. [41] GARZEL B, ZHANG L, HUANG SM, et al.A change in bile flow: looking beyond transporter inhibition in the development of drug-induced cholestasis[J]. Curr Drug Metab, 2019, 20(8): 621-632. [42] GAO YD, ZHU A, LI LD, et al.Cytotoxicity and underlying mechanism of evodiamine in HepG2 cells[J]. Journal of Peking University (Health Science)(北京大学学报医学版), 2021, 53(6): 1107-1114. [43] SU HZ, LI Y, ZHANG ZR, et al.Protecting effects and mechanisms of Yinchenhao decoction on ANIT induced intrahepatic cholestasis in mice[J]. Shanghai Journal of Traditional Chinese Medicine(上海中医药杂志), 2017, 51(S1): 172-176. [44] LI XM, ZHANG XB.Drug induced liver injury[J]. Dermatology Bulletin(皮肤科学文摘), 2016, 33(6): 771-776. [45] FU D, CARDONA P, HO H, et al.Novel mechanisms of valproate hepatotoxicity: impaired mrp2 trafficking and hepatocyte depolarization[J]. Toxicol Sci, 2019, 171(2): 431-442. [46] KAST HR, GOODWIN B, TARR P T, et al.Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor[J]. J Biol Chem, 2002, 277(4): 2908-2915. [47] ZHANG Y, LICKTEIG AJ, LIU J, et al.Effects of ablation and activation of Nrf2 on bile acid homeostasis in male mice[J]. Toxicol Appl Pharmacol, 2020, 403: 115170. [48] ZHANG X, WANG T, YANG Y, et al.Tanshinone IIA attenuates acetaminophen-induced hepatotoxicity through HOTAIR-Nrf2-MRP2/4 signaling pathway[J]. Biomed Pharmacother, 2020, 130: 110547. [49] NING C, GAO X, WANG C, et al.Ginsenoside Rg1 protects against acetaminophen-induced liver injury via activating Nrf2 signaling pathway [50] WANG X.Effect of ursolic acid on Nrf2/UGT2B7/BSEP/MRP2 regulatory pathway in liver injury rats and its mechanism[D]. Nanchang: Nanchang University(南昌大学), 2020. [51] GUO HL, HASSAN HM, ZHANG Y, et al.Pyrazinamide induced rat cholestatic liver injury through inhibition of FXR regulatory effect on bile acid synthesis and transport[J]. Toxicol Sci, 2016, 152(2): 417-428. [52] HU Y.Study on the role of bilirubin in cholestatic liver injury induced by oleanolic acid based on FXR and Nrf2 pathways[D].Zunyi: Zunyi Medical University(遵义医科大学), 2022. [53] CHEN H, ZHAO W, YU H, et al.Study on the protective effect of Semen plantaginis aqueous extract against cyclophosphamide induced liver injury in rats, through FXR-mediated regulation of MRP2/BSEP pathway[J]. Pharmacology and Clinics of Chinese Materia Medica(中药药理与临床), 2018, 34(5): 85-90. [54] MOTTINO AD, CATANIA VA.Hepatic drug transporters and nuclear receptors: regulation by therapeutic agents[J]. World J Gastroenterol, 2008, 14(46): 7068-7074. [55] ZHOU X, BI H, JIN J, et al.Effects of praeruptorin A and praeruptorin C, a racemate isolated from peucedanum praeruptorum, on MRP2 through the CAR pathway[J]. Planta Med, 2013, 79(17): 1641-1647. [56] FU R, WANG XN, DING CY, et al.Advances in the study of pregnane X receptor in drug-induced liver injury[J]. Chinese Journal of Modern Applied Pharmacy(中国现代应用药学), 2021, 38(7): 892-896. [57] WANG LL, YU C.Effects of paeonol on the expression and function of MRP2 in HepG2 cells[J]. Journal of Chongqing Medical University(重庆医科大学学报), 2016, 41(2): 164-167. [58] WANG MT.The role of PXR-MRP2 pathway in cyclosporine-induceddrug-induced liver injury[D]. Wuhan: Hubei University of Chinese Medicine(湖北中医药大学), 2020. [59] LIU C, LI SX, GAO Y, et al.Alcohol extract of Swertia mussitii Franch upregulates membrane protein MRP3, nuclear transcription factor SP1 and nuclear receptors PXR and CF in HepG2 cells[J]. Journal of Army Medical University(第三军医大学学报), 2014, 36(10): 1008-1011. |
[1] | SUN Xiaorui, ZHAO Ning, ZHANG Luyong, JIANG Zhenzhou, WANG Xinzhi. Research Progress in Drug-Related Liver Injury in the Treatment of Autoimmune Diseases [J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 523-527. |
[2] | CAO Weiping, ZHANG Shichao, NI Xia, XIE Bing, WANG Xinzhi, XING Mengtao. Research Progress in Liver Injury Caused by Drugs Commonly Used during Pregnancy [J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 528-531. |
[3] | CHEN Qingyu, JIANG Zhenzhou, ZHANG Luyong. Research Progress in Adaptive Response of Hepatocytes in Intrinsic Drug-Induced Liver Injury [J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 532-538. |
[4] | CHEN Huan, LIANG Jun, ZHAO Wei, XIA Qingrong. Clinical Features and Risk Factors of Liver Injury Induced by Atypical Antipsychotic Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 410-414. |
[5] | LONG Minjuan, ZHAO Xu, GUO Longxin, CAI Yuhan, LIN Li, ZHU Shengkai, LIU Wenlong, SONG Haibo, XIAO Xiaohe. Big Data Analysis of Liver Adverse Reactions Monitoring of Chinese and Western Medicines Based on Age Correction and Risk Warning for Dermatologic Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 271-275. |
[6] | TANG Qianhui, ZHU Ying, ZHANG Haoran, ZHANG Luyong, JIANG Zhenzhou. Roles of Hepatocellular NF-κB Signaling Pathway in Triptolide-Induced Indirect Liver Injury [J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 128-138. |
[7] | HU Yaping, ZHANG Aiwu. One Case of Acute Drug-Induced Liver Injury Caused by Tingli Jiangxuezhi Capsules [J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 224-226. |
[8] | LU Jing, YU Shanshan, TONG Fei, LIN Zhuohui, SONG Luyao. One case of severe constipation caused by dapagliflozin [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1071-1074. |
[9] | QIN Jiaqi, ZHANG Fan, LYU Dongxia, HE Zhen, WEI Yuhui. Functions of PXR/CAR-metabolizing enzyme/transporter detoxification system and research progress [J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 709-715. |
[10] | BUCHANAN James. Assessment of drug-induced liver injury via nR modified Hy’s law and PALT [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 117-120. |
[11] | CHEN Chongze, LI Jie, KUANG Lian, TAN Xuewen, LIU Minhui, LIU Xi, ZHENG Yanchai, JIN Hongtao. Characterization of adverse reactions associated with drug-induced liver injury in 448 inpatients [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 697-704. |
[12] | LI Rongrong, LI Meng, GOU Yue, LUO Qiong, LYU Hua, SUN Xin, LIU Chenghai. Clinical characteristics and risk factors of 113 cases of anti-neoplastic drug-induced liver injury [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 505-510. |
[13] | YAO Keyu, ZHANG Shuqi, JIN Rui, LIU Lihong, ZHU Yan. Comparative study on data set of drug-induced liver injury [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 568-573. |
[14] | CHEN Chao, ZHU Lan, LIU Lihong, HAN Jiayin, ZHU Yan. Characteristics of Psoralea corylifolia induced liver injury [J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 449-453. |
[15] | WANG Yu, HUANG Jingyi, HOU Lixin, LI Shuang, CUI Yongkang, HUANG Lanwei. Humoral immune characteristics of peripheral blood of CAP patients with antibiotic-associated DILI [J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 132-135. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||